TrialBMJ (Clinical research ed.)2023

Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial.

Fei Ma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.